Annabelle Carolin Weldert

Annabelle Carolin Weldert

Auto-generated profile, based on publicly available information

Annabelle Carolin Weldert

Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg-University, Staudingerweg 5, 55128 Mainz, Germany

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 June 2025 in RSC Medicinal Chemistry
Verified
Journal Article
Open access
PDF file
AWAnnabelle C. Weldert
Annabelle C. Weldert
AFAriane F. Frey
Ariane F. Frey
MKMackenzie Woestman Krone
Mackenzie Woestman Krone
FKFranziska Krähe
Franziska Krähe
HKHannah Kuhn
Hannah Kuhn
FBFabian Barthels
Fabian Barthels
Iterative PROTAC design meets molecular fine-tuning—a medicinal chemistry journey to targeted METTL3 degradation.

24 October 2024 in Angewandte Chemie International Edition
Verified
Journal Article
Open access
JMJ. Laurenz Meidner
J. Laurenz Meidner
AFAriane F. Frey
Ariane F. Frey
RZRobert A. Zimmermann
Robert A. Zimmermann
MSMark O. Sabin
Mark O. Sabin
ZNZarina Nidoieva
Zarina Nidoieva
FBFabian Barthels
Fabian Barthels
RNA methylation is a metabolic process validated for its association with various diseases, and thus, RNA methyltransferases (MTases) have become increasingly important in drug discovery. Yet, most frequently utilized RNA MTase assays are limited in their throughput and hamper this rapidly evolving field of medicinal chemistry. In this study, we describe a modular nanomole scale building block system that allowed the identification of tailored fluorescent MTase probes to unlock a broad selection of MTase drug targets for fluorescence‐based binding assays. Probe candidates were initially prepared on a 4 nanomole scale and could be tested directly from crude reaction mixtures to allow rapid probe identification and optimization. Using an alkyne‐azide click late‐stage functionalization strategy and in silico protein databank mining, we established a selection of fluorescent probes suitable for relevant drug targets from the METTL and NSUN families, as well as bacterial and viral MTases. Using this concept, a high‐throughput screening on the unexplored drug target METTL1 discovered three hit compounds with micromolar potency providing a (1 H ‐pyrazol‐4‐yl)pyridine‐based starting point for METTL1 drug discovery.

1 March 2024 in ACS Medicinal Chemistry Letters
Verified
Journal Article
Closed access
Santo PrevitiSanto Previti
Santo Previti
Roberta EttariRoberta Ettari
Roberta Ettari
ECElsa Calcaterra
Elsa Calcaterra
MRMichele Roggia
Michele Roggia
BNBenito Natale
Benito Natale
MZMaria Zappalà
Maria Zappalà

18 January 2024 in Communications Chemistry
Verified
Journal Article
Open access
PDF file
FMFrancisco Javier Medrano
Francisco Javier Medrano
SHSergio de la Hoz-Rodríguez
Sergio de la Hoz-Rodríguez
SMSergio Martí
Sergio Martí
KAKemel Arafet
Kemel Arafet
TSTanja Schirmeister
Tanja Schirmeister
FAFlorenci V. Gonzalez Adelantado
Florenci V. Gonzalez Adelantado
The coronavirus disease 2019 (COVID-19) pandemic continues to represent a global public health issue. The viral main protease (Mpro) represents one of the most attractive targets for the development of antiviral drugs. Herein we report peptidyl nitroalkenes exhibiting enzyme inhibitory activity against Mpro (Ki: 1–10 μM) good anti-SARS-CoV-2 infection activity in the low micromolar range (EC50: 1–12 μM) without significant toxicity. Additional kinetic studies of compounds FGA145, FGA146 and FGA147 show that all three compounds inhibit cathepsin L, denoting a possible multitarget effect of these compounds in the antiviral activity. Structural analysis shows the binding mode of FGA146 and FGA147 to the active site of the protein. Furthermore, our results illustrate that peptidyl nitroalkenes are effective covalent reversible inhibitors of the Mpro and cathepsin L, and that inhibitors FGA145, FGA146 and FGA147 prevent infection against SARS-CoV-2.

10 December 2025 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
AHAriane F. Hübner
Ariane F. Hübner
AWAnnabelle C. Weldert
Annabelle C. Weldert
TMTessa Marciniak
Tessa Marciniak
FHFlorian Hof
Florian Hof
VBVivien S. Beck
Vivien S. Beck
FBFabian Barthels
Fabian Barthels
The tRNA m1G37 methyltransferase (TrmD) is considered essential in various bacteria, including Staphylococcus aureus, a pathogen responsible for a wide range of diseases. Here, we have performed a high-throughput nanomole-scale synthesis campaign (nanoSAR) by late-stage copper(I)-catalyzed alkyne–azide cycloaddition (CuAAC)-functionalizing a library of structurally diverse azides (N = 320) to a pyrrolopyrimidone alkyne. We have identified selective S. aureus TrmD inhibitors with inhibitory activity in the nanomolar to low micromolar range using a direct-to-biology assay read-out. A carbamate-masked guanidine intermediate of the lead structure selectively inhibited S. aureus growth at low micromolar concentrations in cell-based assays, while Gram-negative bacteria and an off-target panel of methyltransferases were not affected. Subsequent cocrystallization resulted in a crystal structure of S. aureus TrmD bound to an inhibitor, providing detailed insights into its binding mode and enabling future structure-guided optimization.

8 February 2024 in Journal of Chemical Education
Verified
Journal Article
Closed access
SHStefan Josef Hammerschmidt
Stefan Josef Hammerschmidt
FBFabian Barthels
Fabian Barthels
AWAnnabelle C. Weldert
Annabelle C. Weldert
KCKersten Christian
Kersten Christian